Alzheimer's disease (AD) is classically characterized by alterations in memory consolidation. With the advent of diagnostic biomarkers, some patients clinically diagnosed with AD display biomarkers inconsistent with the diagnosis.
Objective
We aimed to explore differences in memory consolidation and neurodegeneration of the temporal and parietal lobes as a function of amyloid-β status in amnestic mild cognitive impairment (aMCI).
Methods
We examined differences in memory consolidation and neurodegeneration between patients diagnosed with amyloid-β positive aMCI (Aβ+ N = 78), amyloid-β negative aMCI (Aβ− N = 48), and healthy participants (HP; N = 41), within a well-characterized clinical cohort.
Results
Aβ+ exhibited more pronounced consolidation impairments compared to Aβ−, while Aβ− faced more consolidation challenges than HP. Both Aβ+ and Aβ− were similar in hippocampal volume and entorhinal thickness, but Aβ+ had thinner inferior parietal cortex than Aβ−. Using 18F-fluoro-deoxyglucose-positron emission tomography, metabolism in both temporal and parietal regions was lower in Aβ+ relative to Aβ−.
Conclusions
These findings suggest pathologies other than AD likely contribute to memory consolidation difficulties in aMCI, and neurodegeneration of the parietal cortex in combination with hypometabolism may contribute to more pronounced consolidation problems in Aβ+.
McKhannGDrachmanDFolsteinM, et al.Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group* under the auspices of department of health and human services task force on Alzheimer's disease. Neurology1984; 34: 939–939.
2.
KlunkWEEnglerHNordbergA, et al.Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B. Ann Neurol2004; 55: 306–319.
3.
SmallGWKepeVErcoliLM, et al.PET of brain amyloid and tau in mild cognitive impairment. N Engl J Med2006; 355: 2652–2663.
4.
HanssonOSeibylJStomrudE, et al.CSF Biomarkers of Alzheimer's disease concord with amyloid-β PET and predict clinical progression: a study of fully automated immunoassays in BioFINDER and ADNI cohorts. Alzheimers Dement2018; 14: 1470–1481.
5.
AlbertMSDekoskySTDicksonD, et al.The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement2011; 7: 270–279.
6.
DuboisBFeldmanHHJacovaC, et al.Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurol2014; 13: 614–629.
7.
JackCRJrBennettDABlennowK, et al.NIA-AA research framework: toward a biological definition of Alzheimer's disease. Alzheimers Dement2018; 14: 535–562.
8.
McKhannGMKnopmanDSChertkowH, et al.The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement2011; 7: 263–269.
9.
CaroliAPrestiaAGalluzziS, et al.Mild cognitive impairment with suspected nonamyloid pathology (SNAP) prediction of progression. Neurology2015; 84: 508–515.
10.
BurnhamSCBourgeatPDoréV, et al.Clinical and cognitive trajectories in cognitively healthy elderly individuals with suspected non-Alzheimer's disease pathophysiology (SNAP) or Alzheimer's disease pathology: a longitudinal study. Lancet Neurol2016; 15: 1044–1053.
11.
JackCRJrBennettDABlennowK, et al.A/T/N: an unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology2016; 87: 539–547.
12.
BejaninASchonhautDRLa JoieR, et al.Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer’s disease. Brain2017; 140: 3286–3300.
AllyBAHusseyEPKoPC, et al.Pattern separation and pattern completion in Alzheimer's disease: evidence of rapid forgetting in amnestic mild cognitive impairment. Hippocampus2013; 23: 1246–1258.
15.
ClarensMFCrivelliLCalandriI, et al.Neuropsychological profile of Alzheimer’s disease based on amyloid biomarker findings results from a south American cohort. Appl Neuropsychol Adult2022; 29: 345–350.
16.
TomadessoCde La SayetteVde FloresR, et al.Neuropsychology and neuroimaging profiles of amyloid-positive versus amyloid-negative amnestic mild cognitive impairment patients. Alzheimers Dement (Amst)2018; 10: 269–277.
17.
PappKVAmariglioREMorminoEC, et al.Free and cued memory in relation to biomarker-defined abnormalities in clinically normal older adults and those at risk for Alzheimer’s disease. Neuropsychologia2015; 73: 169–175.
18.
WeigandAJBangenKJThomasKR, et al.Is tau in the absence of amyloid on the Alzheimer’s continuum?: a study of discordant PET positivity. Brain Commun2020; 2: fcz046.
19.
WeigandAJEdwardsLThomasKR, et al.Comprehensive characterization of elevated tau PET signal in the absence of amyloid-beta. Brain Commun2022; 4: fcac272.
20.
RibeiroFGuerreiroMDe MendonçaA. Verbal learning and memory deficits in mild cognitive impairment. J Clin Exp Neuropsychol2007; 29: 187–197.
21.
AlvarezPSquireLR. Memory consolidation and the medial temporal lobe: a simple network model. Proc Natl Acad Sci U S A1994; 91: 7041–7045.
22.
HänggiJStrefferJJänckeL, et al.Volumes of lateral temporal and parietal structures distinguish between healthy aging, mild cognitive impairment, and Alzheimer's disease. J Alzheimers Dis2011; 26: 719–734.
23.
SmitsLLTijmsBMBenedictusMR, et al.Regional atrophy is associated with impairment in distinct cognitive domains in Alzheimer's disease. Alzheimers Dement2014; 10: S299–S305.
24.
MoulinCJJamesNFreemanJE, et al.Deficient acquisition and consolidation: intertrial free recall performance in Alzheimer’s disease and mild cognitive impairment. J Clin Exp Neuropsychol2004; 26: 1–10.
25.
DickersonBCBakkourASalatDH, et al.The cortical signature of Alzheimer's disease: regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloid-positive individuals. Cereb Cortex2009; 19: 497–510.
26.
DevanandDPBansalRLiuJ, et al.MRI Hippocampal and entorhinal cortex mapping in predicting conversion to Alzheimer's disease. Neuroimage2012; 60: 1622–1629.
27.
KillianyRHymanBGomez-IslaT, et al.MRI Measures of entorhinal cortex vs hippocampus in preclinical AD. Neurology2002; 58: 1188–1196.
28.
MosconiLBertiVGlodzikL, et al.Pre-clinical detection of Alzheimer's disease using FDG-PET, with or without amyloid imaging. J Alzheimers Dis2010; 20: 843–854.
29.
SperlingRAAisenPSBeckettLA, et al.Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement2011; 7: 280–292.
30.
PfefferRIKurosakiTTHarrahCHJr, et al.Measurement of functional activities in older adults in the community. J Gerontol1982; 37: 323–329.
31.
DuaraRLoewensteinDPotterE, et al.Medial temporal lobe atrophy on MRI scans and the diagnosis of Alzheimer disease. Neurology2008; 71: 1986–1992.
32.
KoedamELGELehmannMVan Der FlierWM, et al.Visual assessment of posterior atrophy development of a MRI rating scale. Eur Radiol2011; 21: 2618–2625.
33.
LehmannMKoedamELGEBarnesJ, et al.Posterior cerebral atrophy in the absence of medial temporal lobe atrophy in pathologically-confirmed Alzheimer's disease. Neurobiol Aging2012; 33: 627.e621–627.e612.
34.
WahlundL-OJulinPJohanssonS-E, et al.Visual rating and volumetry of the medial temporal lobe on magnetic resonance imaging in dementia: a comparative study. J Neurol Neurosurg Psychiatry2000; 69: 630–635.
35.
FolsteinMFFolsteinSEMcHughPR. Mini-mental state”: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res1975; 12: 189–198.
36.
WilkinsonGRobertsonG. Wide Range Achievement Test 4 (WRAT4). Lutz, FL: Psychological Assessment Resources, 2006.
37.
KauferDICummingsJLKetchelP, et al.Validation of the NPI-Q, a brief clinical form of the neuropsychiatric inventory. J Neuropsychiatry Clin Neurosci2000; 12: 233–239.
38.
DelisDCKramerJHKaplanE, et al.California verbal learning test. San Antonio, TX: Psychological Corporation, 2000.
39.
KeithCMMcCuddyWTLindbergK, et al.Procedural learning and retention relative to explicit learning and retention in mild cognitive impairment and Alzheimer's disease using a modification of the trail making test. Neuropsychol Dev Cogn B Aging Neuropsychol Cogn2023; 30: 669–686.
40.
CurielRELoewensteinDARosselliM, et al.Semantic intrusions and failure to recover from semantic interference in mild cognitive impairment: relationship to amyloid and cortical thickness. Curr Alzheimer Res2018; 15: 848–855.
41.
KitaigorodskyMCroccoECuriel-CidRE, et al.The relationship of semantic intrusions to different etiological subtypes of MCI and cognitively healthy older adults. Alzheimers Dement (Amst)2021; 13: e12192.
42.
HuoYXuZXiongY, et al.3D Whole brain segmentation using spatially localized atlas network tiles. Neuroimage2019; 194: 105–119.
43.
GaserCDahnkeRThompsonPM, et al.CAT: a computational anatomy toolbox for the analysis of structural MRI data. GigaScience2024; 13: giae049.
44.
DestrieuxCFischlBDaleA, et al.Automatic parcellation of human cortical gyri and sulci using standard anatomical nomenclature. Neuroimage2010; 53: 1–15.
45.
SchmidtPGaserCArsicM, et al.An automated tool for detection of FLAIR-hyperintense white-matter lesions in multiple sclerosis. Neuroimage2012; 59: 3774–3783.
46.
LavelyWCScarfoneCCevikalpH, et al.Phantom validation of coregistration of PET and CT for image-guided radiotherapy. Med Phys2004; 31: 1083–1092.
47.
AlvesLCardosoSSilvaD, et al.Neuropsychological profile of amyloid-positive versus amyloid-negative amnestic mild cognitive impairment. J Neuropsychol2021; 15: 41–52.
48.
LoewensteinDACurielREDeKoskyS, et al.Utilizing semantic intrusions to identify amyloid positivity in mild cognitive impairment. Neurology2018; 91: e976–e984.
49.
HildebrandtHHaldenwangerAElingP. False recognition correlates with amyloid-β 1–42 but not with total tau in cerebrospinal fluid of patients with dementia and mild cognitive impairment. J Alzheimers Dis2009; 16: 157–165.
50.
Costoya-SánchezAMoscosoASilva-RodríguezJ, et al.Increased medial temporal tau positron emission tomography uptake in the absence of amyloid-β positivity. JAMA Neurol2023; 80: 1051.
51.
EricksonPSimrénJBrumWS, et al.Prevalence and clinical implications of a β-amyloid–negative, tau-positive cerebrospinal fluid biomarker profile in Alzheimer disease. JAMA Neurol2023; 80: 969.
52.
LimYYMaruffPPietrzakRH, et al.Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer’s disease. Brain2014; 137: 221–231.
53.
WorsleyKFaddaLCaltagironeC. Episodic memory impairment in patients with Alzheimer’s disease is correlated with entorhinal cortex atrophy. J Neurol2007; 254: 774–781.
54.
RaoYLGanarajaBMurlimanjuB, et al.Hippocampus and its involvement in Alzheimer’s disease: a review. 3 Biotech2022; 12: 55.
55.
JacobsHIVan BoxtelMPJollesJ, et al.Parietal cortex matters in Alzheimer's disease: an overview of structural, functional and metabolic findings. Neurosci Biobehav Rev2012; 36: 297–309.
56.
GreeneSJKillianyRJ. Subregions of the inferior parietal lobule are affected in the progression to Alzheimer's disease. Neurobiol Aging2010; 31: 1304–1311.
57.
CrutchSJLehmannMSchottJM, et al.Posterior cortical atrophy. Lancet Neurol2012; 11: 170–178.
58.
FerreiraDMohantyRMurrayME, et al.Does a truly hippocampal sparing subtype of Alzheimer’s disease really exist?Alzheimers Dement2021; 17: e056368.
59.
RichardsBAChertkowHSinghV, et al.Patterns of cortical thinning in Alzheimer's disease and frontotemporal dementia. Neurobiol Aging2009; 30: 1626–1636.
60.
MöllerCHafkemeijerAPijnenburgYA, et al.Different patterns of cortical gray matter loss over time in behavioral variant frontotemporal dementia and Alzheimer's disease. Neurobiol Aging2016; 38: 21–31.
61.
KeithCMHautMWD’HaeseP-F, et al.More similar than different: memory, executive functions, cortical thickness, and glucose metabolism in biomarker-positive Alzheimer’s disease and behavioral variant frontotemporal dementia. J Alzheimers Dis Rep2024; 8: 57–73.
62.
HanseeuwBJSchultzAPBetenskyRA, et al.Decreased hippocampal metabolism in high-amyloid mild cognitive impairment. Alzheimers Dement2016; 12: 1288–1296.
63.
JeonSYYiDByunMS, et al.Differential patterns of regional cerebral hypometabolism according to the level of cerebral amyloid deposition in patients with amnestic mild cognitive impairment. Neurosci Lett2016; 632: 104–108.
64.
CeramiCDella RosaPAMagnaniG, et al.Brain metabolic maps in mild cognitive impairment predict heterogeneity of progression to dementia. Neuroimage Clin2015; 7: 187–194.
65.
TannerJAIaccarinoLEdwardsL, et al.Amyloid, tau and metabolic PET correlates of cognition in early and late-onset Alzheimer’s disease. Brain2022; 145: 4489–4505.
66.
KeithCMHautMWWilhelmsenK, et al.Frontal and temporal lobe correlates of verbal learning and memory in aMCI and suspected Alzheimer’s disease dementia. Neuropsychol Dev Cogn B Aging Neuropsychol Cogn2023; 30: 923–939.
67.
SeltzerBPandyaDN. Further observations on parieto-temporal connections in the rhesus monkey. Exp Brain Res1984; 55: 301–312.
68.
WuYSunDWangY, et al.Tracing short connections of the temporo-parieto-occipital region in the human brain using diffusion spectrum imaging and fiber dissection. Brain Res2016; 1646: 152–159.
69.
OlsonIRBerryhillM. Some surprising findings on the involvement of the parietal lobe in human memory. Neurobiol Learn Mem2009; 91: 155–165.
70.
NagSYuLWilsonRS, et al.TDP-43 pathology and memory impairment in elders without pathologic diagnoses of AD or FTLD. Neurology2017; 88: 653–660.
71.
WalkerJMGoetteWFarrellK, et al.The relationship between hippocampal amyloid beta burden and spatial distribution of neurofibrillary degeneration. Alzheimers Dement2023; 19: 3158–3170.
72.
FixemerSAmeliCHammerG, et al.Microglia phenotypes are associated with subregional patterns of concomitant tau, amyloid-β and α-synuclein pathologies in the hippocampus of patients with Alzheimer’s disease and dementia with Lewy bodies. Acta Neuropathol Commun2022; 10: 36.
73.
PijnenburgYALVerweyNAVan Der FlierWM, et al.Discriminative and prognostic potential of cerebrospinal fluid phosphoTau/tau ratio and neurofilaments for frontotemporal dementia subtypes. Alzheimers Dement (Amst)2015; 1: 505–512.
74.
KnopmanDSLundtESTherneauTM, et al.Entorhinal cortex tau, amyloid-β, cortical thickness and memory performance in non-demented subjects. Brain2019; 142: 1148–1160.
75.
RobinsonCGLeeJMinPH, et al.Significance of a positive tau PET scan with a negative amyloid PET scan. Alzheimers Dement2024; 20: 1923–1932.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
